Duloxetine News and Research RSS Feed - Duloxetine News and Research

Duloxetine is approved in the United States for the acute and maintenance treatment of major depressive disorder, the acute treatment of generalized anxiety disorder, and the management of diabetic peripheral neuropathic pain and fibromyalgia in adults aged 18 years and older. Duloxetine is not approved for use in pediatric patients.
BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BDSI enrolls first patient in Clonidine Topical Gel Phase 3 trial for treatment of painful diabetic neuropathy

BioDelivery Sciences International, Inc. announced today the enrollment of the first patient in the RHAPSODY Study, a Phase 3 clinical trial of Clonidine Topical Gel for the treatment of painful diabetic neuropathy. [More]
Research report on China's duloxetine market

Research report on China's duloxetine market

Research and Markets has announced the addition of the "Investigation Report on China Duloxetine Market" report to their offering. [More]
Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly's revenue decreases 2% to $5.809 billion in fourth quarter 2013

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2013. Certain financial information for 2013 and 2012 are presented on both a reported and a non-GAAP basis. [More]

Vitamin D may be adjunct for patients with fibromyalgia syndrome, say researchers

Patients with fibromyalgia syndrome (FMS) typically have widespread chronic pain and fatigue. For those with low vitamin D levels, vitamin D supplements can reduce pain and may be a cost-effective alternative or adjunct to other treatment, say researchers in the January 2014 issue of PAIN-. [More]
Research report on global pain management devices market

Research report on global pain management devices market

Research and Markets has announced the addition of the "Global Pain Management Devices Market Report 2013-2018 " report to their offering. [More]
IQWiG completes first health economic evaluation

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results. [More]
Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder. [More]
Duloxetine drug alleviates pain from chemotherapy

Duloxetine drug alleviates pain from chemotherapy

Among patients with painful chemotherapy-induced peripheral neuropathy, use of the anti-depressant drug duloxetine for 5 weeks resulted in a greater reduction in pain compared with placebo, according to a study in the April 3 issue of JAMA. [More]

Duloxetine drug reduces painful chemotherapy-induced peripheral neuropathy in majority of patients

The antidepressant drug duloxetine, known commercially as Cymbalta, helped relieve painful tingling feelings caused by chemotherapy in 59 percent of patients, a new study finds. This is the first clinical trial to find an effective treatment for this pain. [More]

Pelvic floor muscle training effective for adult women with urinary incontinence

A type of exercise called pelvic floor muscle training is effective for treating adult women with urinary incontinence (the involuntary loss of urine) without risk of side effects, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality (AHRQ). The report also found that drug-based treatments can be effective, but the degree of benefit is low and side effects are common. [More]
Antidepressants can play a key role in relieving pain associated with OA

Antidepressants can play a key role in relieving pain associated with OA

Antidepressants can play a key role in alleviating painful conditions like osteoarthritis and may result in fewer side effects than traditionally prescribed drug regimes, such as anti-inflammatories and opioids, according to a perspective paper published online ahead of print publication by the International Journal of Clinical Practice. [More]
UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

UTHealth to study BMS-820836 in Phase II trial for major depressive disorder

A new medication to treat major depressive disorder in patients who have not responded to other antidepressants is being studied in a Phase II clinical trial by researchers at The University of Texas Health Science Center at Houston. [More]
Lilly second quarter total revenue increases 9% to $6.253 billion

Lilly second quarter total revenue increases 9% to $6.253 billion

Eli Lilly and Company today announced financial results for the second quarter of 2011. [More]
Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Health Canada approves Eli Lilly's Cymbalta for chronic low back pain treatment

Eli Lilly Canada announced today that Health Canada has approved Cymbalta for the management of chronic low back pain. [More]

Eli Lilly total revenue increases 6% to $5.839 billion for first quarter 2010

Eli Lilly and Company today announced financial results for the first quarter of 2011. [More]
New guideline on most effective treatments for diabetic nerve pain

New guideline on most effective treatments for diabetic nerve pain

The American Academy of Neurology has issued a new guideline on the most effective treatments for diabetic nerve pain, the burning or tingling pain in the hands and feet that affects millions of people with diabetes. The guideline is published in the April 11, 2011, online issue of Neurology®, the medical journal of the American Academy of Neurology, and will be presented April 11, 2011, at the American Academy of Neurology's Annual Meeting in Honolulu. [More]

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

The National Association For Continence awarded Gamal Ghoniem, MD, with the Rodney Appell Continence Care Champion Award at the Society for Urodynamics and Female Urology Awards Reception on March 4, held during the 2011 SUFU Winter Meeting in Phoenix, AZ. [More]

Prolonged exposure to antidepressants can induce tardive dysphoria

In the current issue of Psychotherapy and Psychosomatics a new important side effect of antidepressant drugs is described: tardive dysphoria. [More]

AstraZeneca, Targacept commence TC-5214 Phase 2b clinical trial for major depressive disorder

AstraZeneca and Targacept, Inc. today announced initiation of a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a "switch" monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy. This study is in addition to the companies' Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD. [More]

Lilly fourth quarter worldwide total revenue increases 4% to $6.187 billion

Eli Lilly and Company today announced financial results for the fourth quarter and full year of 2010. [More]